Table 1 Characteristics of PsA patients with arthritis mutilans
From: Psoriatic arthritis mutilans: a descriptive study from a Brazilian tertiary center
Variable | N = 17 |
|---|---|
Age (years) | 58 [53; 68] |
Male gender | 12 (70) |
Caucasian ethnicity | 9 (53) |
Age at onset—skin (years) | 33 [27; 38.5] |
Age at onset—joint (years) | 35 [27; 42] |
Psoriasis duration (years) | 25 [20; 34.5] |
Arthritis duration (years) | 22 [17; 31] |
Axial involvement | 10/16 (62.5) |
Syndesmophytes/parasyndesmophytes | 9/16 (56) |
Radiographic sacroiilitis* | 7/16 (44) |
HLA-B27 positive | 9/13 (69) |
Comorbidity n (%) | |
Hypertension | 13 (76) |
Dyslipidemia | 10 (59) |
Metabolic syndrome | 9 (53) |
Prediabetes | 6 (35) |
Obesity (BMI ≥ 30 kg/m2) | 4 (24) |
Diabetes mellitus | 2 (12) |
Thyroid disease | 3 (18) |
Hypothyroidism | 2 (12) |
Hyperthyroidism | 1 (6) |
Psychiatric disorders | 4 (24) |
Depression | 2 (12) |
Anxiety | 2 (12) |
Cancer | 3 (18) |
Osteoporosis | 6 (35) |
Fragility fracture | 4 (24) |
Treatment n (%) | |
History of csDMARD use | 17 (100) |
MTX | 16 (94) |
Leflunomide | 9 (53) |
Sulfasalazine | 4 (24) |
Cyclosporine | 3 (18) |
bDMARD | 10 (59) |
Infliximab | 8 (47) |
Etanercept | 4 (24) |
Adalimumab | 4 (24) |
Golimumab | 1 (6) |
Secukinumab | 2 (12) |
Abatacept | 2 (12) |